Lamb Lawrence 4

What Happened Lawrence Lamb, Executive Vice President and Chief Scientific Officer of IN8BIO (INAB), was granted a derivative award for 54,000 shares on May 9, 2026. The grant is reported at a $0.00 acquisition price (derivative award), so there was no cash exchanged at grant. The award will vest over four scheduled dates (25% each), subject to continued service.

Key Details

• Transaction date: May 9, 2026; Form 4 filed May 12, 2026.
• Transaction type/code: A — grant/award (derivative). Reported acquisition: 54,000 shares at $0.00.
• Vesting: 25% vests on each of Nov 9, 2026; May 9, 2027; Nov 9, 2027; and May 9, 2028, contingent on continued service (footnote F1).
• Shares owned after transaction: Not specified in the filing.
• No 10b5-1 plan, tax-withholding sale, or immediate sale of shares is indicated in the reported transaction.
• Timeliness: filing date is May 12, 2026 for a May 9, 2026 grant (check the official SEC filing for any timeliness flags).

Context This is a time-based compensation award (a derivative grant that could be options or RSUs depending on plan terms) rather than an open-market purchase or sale. Because vesting is tied to continued service, the grant is primarily a retention/compensation event — its future value will depend on IN8BIO’s stock price and the specific award terms. Such grants do not by themselves signal an insider buying or selling shares in the market.